<DOC>
	<DOCNO>NCT00141791</DOCNO>
	<brief_summary>The primary objective study assess efficacy safety etanercept 25 mg give twice weekly subject moderate severe persistent asthma .</brief_summary>
	<brief_title>Study Evaluating Etanercept Moderate Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Moderate severe persistent asthma least 1 year Demonstrated reversibility least 9 % ( FEV1 ) 50 % 80 % predicted Subjects must highdose inhaled corticosteroid ( ICS ) Previous treatment etanercept Current use cigarettes Significant concurrent medical condition time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Anti-Asthmatic Agents</keyword>
	<keyword>Receptors</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
</DOC>